JLF peptide candidate list

Alexander Young ยท Source: patient-supplied JLF design workbook.

Download plain cell values as CSV (epitope styling is only in this HTML)

Sheet1

#CANDIDATE NEOANTIGENGENECANDIDATE NEOANTIGEN AMINO ACID SEQUENCE WITH FLANKING RESIDUESRESTRICTING HLA ALLELECANDIDATE NEOANTIGEN AMINO ACID SEQUENCE MW (CLIENT)
1.0jlf-100-203.MT.381.SMAD4SMAD4QVGETFKVPSSCPIVTVDGYVDPSGEDRFCLGQLSNVHRTEAIERARLHIGHLA-C*05:015585.205199999999
2.0jlf-100-203.MT.365.KIF1CKIF1CARTVAATNMNETSSRSHAVFTIVFTLRCHDQLTGLDSEKVSKISLVDLAGSHLA-A*02:015479.121499999999
3.0jlf-100-203.MT.318.GALK2GALK2TVSMVPADKLPSFLANVHKAYYQRSDGSLAPEKQSLFATKPGDGALVLLEAHLA-C*03:045433.1522
4.0jlf-100-203.MT.204.KMT2EKMT2EKKRRFYQLLDSVYSETSTPTPSPYAPPTHTDITPMDPSFATPPRIKSDDETHLA-C*03:045784.335000000002
5.0jlf-100-203.MT.75.SLC39A10SLC39A10LGDFAVLLKAGMTVKQAIVYNLLSAIMAYIGMLIGTAVGQYANNITLWIFAHLA-A*02:015463.5201
6.0jlf-100-203.MT.30.PRRC2CPRRC2CKETDEVSNTKSSSQIPAQPSVAKVPNGKGPSFNQERGTSSHLPPPPKLLAQHLA-B*07:025367.8923
7.0jlf-100-203.MT.321.TLN2TLN2VTNVTSLLKTVKAVEDEATRGTRALQATIECIKQELTVFQSKDVPEKTSSPHLA-A*02:015562.265200000001
8.0jlf-100-203.MT.298.BRCA2BRCA2KFVKGRQTPKHISESLGAEVDPDMSRSSSLATPPTLSSTVLIVRNEEASETHLA-B*07:025485.056899999998
9.0jlf-100-203.MT.223.HNF4GHNF4GGSSTDINVKKIASIGDVCESMKQQLFVLVEWAKYIPAFCELPLDDQVALLRHLA-A*02:01/DPA1*01:03-DPB1*02:015683.573199999998
10.0jlf-100-203.MT.197.LRCH4LRCH4PEAACQLVSLEGLSLYHNCLRCLNPVLGNLTALTYLNLSRNQLSLLPPYICHLA-B*07:025616.556699999999
11.0jlf-100-203.MT.247.CCDC6CCDC6KMAQYLEEERHMREENLRLQRKLQRRWREEKPSVDSSPRVSPAHLA-C*05:015351.010800000002
12.0jlf-100-203.MT.20.NBPF15NBPF15QALLTPDEPDKSQGQDLQEQLAEGCKLTQHLVQKLSPENDNDDDEDVQVEVHLA-A*02:015704.030000000002
13.0jlf-100-203.MT.220.FHIP2BFHIP2BSAPSDEASFPGKEALAAFLGWFDYCNHLITEAHTVVADALAKAVAENFFVEHLA-C*05:015472.012500000002
14.0jlf-100-203.MT.102.WDFY1WDFY1ATFHEGKHNISHMSMDIARGLMVTCGTDRIIKIWDMTPVVGCSLATGFSPHHLA-A*02:015571.4401
15.0jlf-100-203.MT.207.AASSAASSNRRAIHDKDYVKAGGILQEDISEACIILGVKRPPEEKLMSRKTYAFFSHTIHLA-B*44:02/DQA1*01:02-DQB1*06:025846.697099999998
16.0jlf-100-203.MT.155.WWC1WWC1RFRLLLRMLEKRQMDRAEHKGELQTEKMMRAAAKDVHRLRGQSCKEPPEVQHLA-B*44:026133.150700000002
17.0jlf-100-203.MT.148.APCAPCEAHEPGMDQDKNPMPAPVEHQICPAGVFHLA-B*44:023045.384599999999
18.0jlf-100-203.MT.395.SMARCA4SMARCA4FLLSTRAGGLGLNLQSADTVIIFDSYWNPHQDLQAQDRAHRIGQQNEVRVLHLA-C*05:015763.354700000002
19.0jlf-100-203.MT.34.ELF3ELF3RDLTSSSSDELSWIIELLEKDGMAFHEALDPGPFDQGSPFAQELLDDGQQAHLA-B*44:025607.987000000001
20.0jlf-100-203.MT.150.APCAPCRCTSVSSLDSFESRSIASSVQSEPCREWHLA-B*44:023134.3704
a The nomenclature convention for candiate neoantigens is JLF-100-YYY-MT.A.ZZZZ where YYY is the patient identifier, A is the mutation #, and ZZZZ is the gene name. Driver genes are noted with light green fill.
b The minimal class I epitope is provided in red letters. The class II epitope is in bold font. For all SNVs or sequences that vary from the wildtype sequence, the AAs are underlined. Flanking residues are included to allow more flexibility for vaccine manufacture.
c CS Bio will evaluate the candidate neoantigen sequence and propose several synthetic lone peptides for attempted manufacture. CS Bio will have to increase the number one of rows such that there is one row per SLP.
d The SLP name is based on the Candidate Neoantigen name.